jayempi
nova laboratories ireland limited - azathioprine - odmítnutí štěpu - imunosupresiva - jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression). jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response. jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – dmards)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidbehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm igg antibodieschronic refractory idiopathic thrombocytopenic purpurajayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (ibd) (crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice. it is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3jayempi is indicated for the treatment of generalised myasthenia gravis. depending on the severity of the disease, jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment.
piperacillin/tazobactam ibigen 2g/0,25g prášek pro infuzní roztok
ibigen, s.r.l., aprilia array - 4948 sodnÁ sŮl piperacilinu; 14176 sodnÁ sŮl tazobaktamu - prášek pro infuzní roztok - 2g/0,25g - piperacilin a inhibitor beta-laktamasy
piperacillin/tazobactam ibigen 4g/0,5g prášek pro infuzní roztok
ibigen, s.r.l., aprilia array - 4948 sodnÁ sŮl piperacilinu; 14176 sodnÁ sŮl tazobaktamu - prášek pro infuzní roztok - 4g/0,5g - piperacilin a inhibitor beta-laktamasy
piperacillin/tazobactam kabi 4g/0,5g prášek pro infuzní roztok
fresenius kabi s.r.o., praha array - 4948 sodnÁ sŮl piperacilinu; 14176 sodnÁ sŮl tazobaktamu - prášek pro infuzní roztok - 4g/0,5g - piperacilin a inhibitor beta-laktamasy
paralen grip horký nápoj pomeranČ a zázvor 500mg/10mg prášek pro perorální roztok v sáčku
opella healthcare czech s.r.o., praha array - 1064 paracetamol; 1122 fenylefrin-hydrochlorid - prášek pro perorální roztok v sáčku - 500mg/10mg - paracetamol, kombinace kromĚ psycholeptik
strepsils pomeranČ s vitaminem c pastilka
reckitt benckiser (czech republic), spol. s r.o., praha array - 83 amylmetakresol; 2163 2,4-dichlorbenzylalkohol; 1311 natrium-askorbÁt; 102 kyselina askorbovÁ - pastilka - dichlorbenzylalkohol
tantogrip pomeranČ 600mg/10mg prášek pro perorální roztok v sáčku
angelini pharma Česká republika s.r.o., brno array - 1064 paracetamol; 1122 fenylefrin-hydrochlorid - prášek pro perorální roztok v sáčku - 600mg/10mg - paracetamol, kombinace kromĚ psycholeptik
celaskon Červený pomeranČ 500mg šumivá tableta
zentiva, k.s., praha array - 102 kyselina askorbovÁ - Šumivá tableta - 500mg - kyselina askorbovÁ (vitamin c)
larymed pomeranČ a med 3mg pastilka
dr. max pharma s.r.o., praha array - 151 benzydamin-hydrochlorid - pastilka - 3mg - benzydamin